Inbiomotion’s news July 14 2022

Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance MAFTEST®analyses of the…